CC241108P17500
- 0.05
- 0.000.00%
The Chemours Newsroom
Chemours Is Maintained at Equal-Weight by Morgan Stanley
Chemours Analyst Ratings
Express News | Chemours Co : Morgan Stanley Cuts Target Price to $25.00 From $30.00
Should You Investigate The Chemours Company (NYSE:CC) At US$20.58?
Barclays Maintains The Chemours(CC.US) With Hold Rating, Raises Target Price to $23
Mizuho Securities Maintains The Chemours(CC.US) With Hold Rating
Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $30
Update: Chemours Shares Jump After Q3 Results Come Ahead of Estimates
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday
The Chemours Company (CC) Q3 2024 Earnings Call Transcript Summary
Chemours Up Over 16%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk
4 Materials Stocks Moving In Monday's Pre-Market Session
Chemours Swings to 3Q Loss But Sales Grow, Beating Market Views
The Chemours | 10-Q: Q3 2024 Earnings Report
Chemours Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
Chemours Non-GAAP EPS of $0.40, Revenue of $1.5B
Express News | Chemours - in Q4, Tss Anticipates a Sequential Low-Teens Net Sales Decline
Earnings Flash (CC) CHEMOURS COMPANY Reports Q3 EPS $0.40
Chemours Expects to Achieve Incremental Run-Rate Cost Savings of Greater Than $250 M Across the Co From 2024 Through 2027 >CC
Express News | Chemours - Anticipates Achieving 50% of Planned Run-Rate Cost Savings by End of 2025